Molecular Profile | BRAF V600E |
Therapy | CI-1040 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Create By | c-seddy |
Update By | c-seddy |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | BRAF V600E | Advanced Solid Tumor | sensitive | CI-1040 | Preclinical | Actionable | In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618). | 20538618 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(20538618) | Gatekeeper mutations mediate resistance to BRAF-targeted therapies. | Full reference... |